Culturally-Tailored Smoking Cessation for Adult American Indian Smokers: A Clinical Trial.
Stevens S Smith, Leah M Rouse, Mark Caskey, Jodi Fossum, Rick Strickland, J Kevin Culhane, Jerry Waukau
Author Information
Stevens S Smith: Department of Medicine and Center for Tobacco Research and Intervention (CTRI), University of Wisconsin School of Medicine and Public Health (UWSMPH), Madison, WI.
Leah M Rouse: Department of Educational Psychology, University of Wisconsin-Milwaukee.
Mark Caskey: Menominee Tribal Clinic, Menominee Indian Tribe of Wisconsin, Keshena, WI.
Jodi Fossum: Menominee Tribal Clinic, Menominee Indian Tribe of Wisconsin, Keshena, WI.
Rick Strickland: UW Spirit of EAGLES, Carbone Cancer Center, UWSMPH, Madison, WI.
J Kevin Culhane: Menominee Tribal Clinic, Menominee Indian Tribe of Wisconsin, Keshena, WI.
Jerry Waukau: Menominee Tribal Clinic, Menominee Indian Tribe of Wisconsin, Keshena, WI.
This collaborative, community-engaged project developed and tested a Culturally-Tailored Treatment (CTT) for American Indian/Alaska Native (AI/AN) smokers in the Menominee tribal community. One hundred three adult AI/AN smokers were randomized to receive either Standard Treatment (= 53) or CTT ( = 50) for smoking cessation. Both treatment conditions included 12 weeks of varenicline and four individual counseling sessions but differed in terms of cultural tailoring of the counseling. The primary outcome was 7-day biochemically-confirmed point-prevalence abstinence (PPA) at the 6-month end-of-study visit. Both intention-to-treat (ITT) and responder-only analyses were conducted. There were no statistically significant group differences in 7-day PPA. The overall ITT abstinence rate at 6 months was 20%; the responder-only rate was 42%. The current study represents the first randomized smoking cessation clinical trial testing a culturally-tailored smoking cessation intervention designed for a specific AI/AN tribal community that combined FDA-approved cessation medication (varenicline) and innovative cultural intervention components.
References
Annu Rev Clin Psychol. 2013;9:675-702
[PMID: 23297788]
J Cancer Educ. 2005 Spring;20(1 Suppl):97-100
[PMID: 15916529]
Am J Prev Med. 2008 Feb;34(2):102-11
[PMID: 18201639]
